More And Better Biotech IPOs, But Step-Ups Still Lag
Executive Summary
Higher valuations, better quality companies, improved aftermarket performance and a broadening investor pool are all conspiring to advance the state of biotech IPOs. But VCs continue to see little step-up at IPO.
You may also be interested in...
Kythera Doubles Down On Double Chins With Bayer Buyback
The biotech buys back rights to its own drug after attaining a more advantageous financial position and successful late-stage results.
Biopharma IPOs Start to Gear Up For 2013 After a Lull
Biopharma and diagnostic IPOs have been relatively quiet since before the U.S. presidential election, but companies are again starting on road shows and updating prospectuses in anticipation of recaptured momentum.
Biopharma IPOs Start To Gear Up For 2013 After A Lull
Biopharma and diagnostic IPOs have been relatively quiet since before the U.S. presidential election, but companies are again starting on road shows and updating prospectuses in anticipation of recaptured momentum.